<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Philis-Tsimikas, Athena</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Insulin Degludec is Superior to Sitagliptin in Improving Glycemic Control in Uncontrolled Patients with Type 2 Diabetes on Oral Agents</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-20</style></pages><abstract><style  face="normal" font="default" size="100%">Insulin degludec is superior to sitagliptin in improving glycemic control in patients with type 2 diabetes mellitus uncontrolled by oral antidiabetic drugs (OADs). This article discusses the results of the comparison of NN1250 with Sitagliptin in Subjects with Type 2 Diabetes Never Treated with Insulin [BEGIN®: EARLY; NCT01046110] trial that compared basal insulin with a dipeptidyl peptidase-4 inhibitor as an add-on to OADs.</style></abstract><number><style face="normal" font="default" size="100%">16</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>